1. The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir1. Issue 2 (14th July 2015) Authors: Wohl, DA; Bhatti, L; Small, CB; Edelstein, H; Zhao, HH; Margolis, DA; DeJesus, E; Weinberg, WG; Ross, LL; Shaefer, MS Journal: HIV medicine Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗